ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the certificate dated November 2, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed Newspaper Publication of the Financial Results for the quarter ended September 30, 2023 for your reference.
AstraZeneca Pharma fall 3% despite healthy Q2 net profit, revenue growth
The stock slipped amid reports of the Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, facing a legal challenge the UK ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday, November 9, 2023
At the Board Meeting of the Company held on Thursday, November 9, 2023, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2023. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors dated September 30, 2023 are enclosed herewith. The Meeting commenced at 1:30 P.M. and concluded at 4:50 P.M. (IST). ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Change in Directorate
We would like to inform that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ms. Hooi Bien Chuah, as an Additional Director (Non-Executive) of the Company, with effect from November 9, 2023. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Thursday, November 9, 2023
At the Board Meeting of the Company held on Thursday, November 9, 2023, the Board of Directors considered and approved the Unaudited Financial Results for the quarter ended September 30, 2023. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday, November 9, 2023
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from September 16, 2023 to November 11, 2023 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that the Company has received an order from the Transfer Pricing Officer being issued under Section 92CA(3) of Income Tax Act, 1961 for the assessment year 2021-22, wherein an adjustment on the legacy issues have been proposed. The estimated tax impact of the adjustments proposed is Rs. 9.17 crores (approx.). The said amount does not involve any interest or penal consequences. The Company will suitably challenge the order in the due course. In this regard, please find the enclosed details as required under the applicable SEBI Circular dated July 13, 2023 for your reference. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificates from the claimant. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Share Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the deceased shareholder.